Search

Objective: To investigate effect of bi-level positive airway pressure combined with seretide on immune function, quality of life and respiratory failure symptoms of patients with COPD complicated with type II respiratory failure. Methods: 157 patients with COPD complicated with type II respiratory failure in our hospital from June 2012 to December 2016 were divided into observation group (n=79) and control group (n=78) according to the random number table method, the patients in the control group were treated with routine treatment such as relieving asthma, relieving spasm, resolving phlegm and anti infection, and combined with Bi-PAP treatment, the patients in the observation group were treated with seretide treatment on the basis of the treatment plan in the control group. Respiratory failure symptoms, immune function and quality of life were compared between the two groups before and after treatment. Results: The effective rate of the observation group after treatment was 89.87% (71/79), which was significantly higher than that of the control group 73.08%(57/78)(P<0.05). After treatment, the respiratory rate, heart rate, arterial partial pressure of carbon dioxide in the two groups were lower than before treatment, and the arterial partial pressure of oxygen was higher than before treatment, and the respiratory rate, heart rate and arterial partial pressure of carbon dioxide in the observation group were lower than those in the control group, and the arterial partial pressure of oxygen was higher than that of the control group (all P<0.05). After treatment, levels of serum immunoglobulin M (IgM),immunoglobulin G (IgG) and immunoglobulin A (IgA) of patients in two groups were significantly higher than those before treatment, and the levels of IgM, IgA and IgG in the observation group after treatment were higher than those in the control group (all P<0. 05). Over time, the St.George Hospital Respiratory Questionnaire (SGRQ) score in the two groups after treatment was decreased gradually, and the SGRQ scores of the observation group at 3 months and 6 months after treatment were lower than that of the control group (all P<0.05). Conclusion: Bi-PAP combined with Seretide can significantly improve the symptoms of respiratory failure in patients with COPD complicated with type II respiratory failure, improve immune function and quality of life of patients, clinical application value is high. [ABSTRACT FROM AUTHOR]